The following is a summary of the Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2024 Earnings Call Transcript:

Financial Performance:

• Catalyst Pharmaceuticals achieved a revenue of $122.7 million in Q2 2024, representing a 23.2% increase year over year.

• Net income before income taxes was $55.8 million, reflecting a 15% increase from the same period last year.

• GAAP net income was reported at $40.8 million, or $0.33 per diluted share, an 8% increase year over year.

• Non-GAAP net income for Q2 2024 was $69.6 million, or $0.56 per diluted share.

Business Progress:

• FIRDAPSEE achieved net sales of $77.4 million in Q2, a 19.2% increase year-over-year.

• FYCOMPA reported stable revenues, expecting to continue in H2 2024.

• AGAMREE demonstrated a strong commercial launch with Q2 revenues of $8.7 million.

• Expansion in ex-U.S. markets through a licensing agreement with Kye Pharma for the commercialization of AGAMREE in Canada.

Opportunities:

• Regulatory approval of FIRDAPSEE's expanded dose and the strong uptake of AGAMREE highlight potential for extended market reach and increased revenue.

• Partnerships in Japan and the newly formed alliance with Kye Pharma in Canada provide opportunity for increased international market penetration.

Risks:

• No explicit risks detected.

More details: Catalyst Pharmaceuticals IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.